Maxim Group Downgrades Reshape Lifesciences to Hold
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Anthony Vendetti has downgraded Reshape Lifesciences (NASDAQ:RSLS) from Buy to Hold.
July 17, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Maxim Group analyst Anthony Vendetti has downgraded Reshape Lifesciences from Buy to Hold, indicating a less optimistic outlook on the stock.
The downgrade from Buy to Hold by a reputable analyst suggests a less favorable view on the stock's short-term performance, which could lead to a decline in investor confidence and a potential drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100